Opinion

When Eli Lilly agreed to acquire Atai Beckley in a deal worth up to US$3.8 billion, it wasn't simply the...

As psychedelic medicine edges closer to mainstream clinical practice, Europe is approaching a pivotal moment that could shape the sector...

For much of the past five years, the psychedelic medicine sector has been driven by a relatively straightforward investment thesis....

As workforce shortages deepen across the country, Australia faces an uncomfortable question: why are we importing healthcare workers to fill...

When historians eventually document the modern psychedelic renaissance in Australia, they will likely focus on a handful of landmark moments....

Beyond SSRIs lies a global battle between pharma, therapy, technology, and the future of human consciousness. For decades, modern psychiatry...

How a tiny Perth microcap quietly ended up inside one of the world’s most important psychiatric experiments At first glance,...

How Australia’s tightly controlled psychedelic medicine framework is now influencing global conversations around mental healthcare, regulation, and biotech investment Australia...

The Quiet Battle Defining a $10 Billion Industry Psychedelic therapy is not just being approved. It is being defined. Behind...

The psychedelic medicine movement has crossed a threshold. What was once relegated to the fringes of science, dismissed by policymakers,...